Deutsche Bank AG Has $477,000 Holdings in Rocket Pharmaceuticals, Inc. $RCKT

Deutsche Bank AG lifted its holdings in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 12.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 71,470 shares of the biotechnology company’s stock after purchasing an additional 7,692 shares during the period. Deutsche Bank AG owned 0.07% of Rocket Pharmaceuticals worth $477,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of RCKT. Signaturefd LLC lifted its holdings in shares of Rocket Pharmaceuticals by 83.6% during the first quarter. Signaturefd LLC now owns 9,024 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 4,108 shares during the period. LJI Wealth Management LLC acquired a new position in shares of Rocket Pharmaceuticals during the first quarter worth $80,000. Victory Capital Management Inc. lifted its holdings in Rocket Pharmaceuticals by 16.1% in the first quarter. Victory Capital Management Inc. now owns 11,929 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 1,658 shares during the period. Powell Investment Advisors LLC acquired a new position in Rocket Pharmaceuticals in the first quarter valued at $83,000. Finally, CWM LLC lifted its holdings in Rocket Pharmaceuticals by 255.0% in the first quarter. CWM LLC now owns 13,223 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 9,498 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Down 2.1%

RCKT opened at $3.32 on Thursday. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.39 and a quick ratio of 6.39. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $22.01. The firm has a market capitalization of $358.23 million, a PE ratio of -1.32 and a beta of 0.65. The company’s 50-day moving average is $3.03 and its 200 day moving average is $5.50.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). During the same period in the prior year, the business posted ($0.74) EPS. As a group, research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Martin Wilson sold 12,109 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $3.02, for a total value of $36,569.18. Following the sale, the general counsel owned 137,054 shares in the company, valued at $413,903.08. This represents a 8.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Elisabeth Bjork bought 10,000 shares of the stock in a transaction that occurred on Wednesday, August 27th. The stock was acquired at an average price of $3.41 per share, for a total transaction of $34,100.00. Following the acquisition, the director directly owned 40,000 shares in the company, valued at $136,400. The trade was a 33.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 36,927 shares of company stock worth $111,413 in the last quarter. Insiders own 24.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Chardan Capital restated a “buy” rating and issued a $11.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, August 20th. Morgan Stanley restated an “equal weight” rating and issued a $7.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Scotiabank dropped their target price on shares of Rocket Pharmaceuticals from $51.00 to $19.00 and set a “sector outperform” rating on the stock in a report on Wednesday, May 28th. Jefferies Financial Group restated a “hold” rating on shares of Rocket Pharmaceuticals in a report on Wednesday, May 28th. Finally, TD Cowen restated a “hold” rating on shares of Rocket Pharmaceuticals in a report on Tuesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $16.73.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.